INOVIO Faces FDA Hurdle for Lead Drug's Accelerated Approval, Reports Limited Cash Runway

summarizeSummary

INOVIO's Q4/FY 2025 results reveal the FDA's preliminary conclusion that its lead drug, INO-3107, may not qualify for accelerated approval, alongside a cash runway extending only into Q4 2026.

check_boxKey Events

• FDA Questions Accelerated Approval Eligibility for Lead Drug

  The FDA accepted the Biologics License Application (BLA) for INO-3107 but issued a preliminary conclusion that INOVIO had not provided adequate information to justify eligibility for the accelerated approval pathway. The FDA granted a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target date of October 30, 2026, instead of the requested priority review.

• Limited Cash Runway Projected

  The company reported cash, cash equivalents, and short-term investments of $58.5 million as of December 31, 2025, projecting this capital will support operations only into the fourth quarter of 2026. This projection does not include any future capital-raising activities.

• Q4 2025 Financial Results

  INOVIO reported a net income of $3.8 million for the fourth quarter of 2025, or $0.06 per basic share. This net income was primarily driven by a $21.2 million non-cash gain on fair value adjustment related to warrant liabilities. The full-year 2025 net loss was $84.9 million.

• New Glioblastoma Collaboration Announced

  INOVIO announced a clinical trial collaboration and supply agreement with Akeso Inc. to evaluate INO-5412 in combination with cadonilimab for the potential treatment of glioblastoma (GBM) in a Dana-Farber Cancer Institute-sponsored Phase 2 trial.

auto_awesomeAnalysis

This filing provides critical updates on INOVIO's financial health and regulatory progress for its lead candidate, INO-3107. The FDA's preliminary conclusion regarding the ineligibility for accelerated approval for INO-3107 is a significant setback, potentially delaying or complicating the path to market for the company's most advanced program. This regulatory uncertainty, combined with a limited cash runway into Q4 2026 without further capital raises, intensifies the financial pressure on the company, reinforcing the "going concern" warning noted in its recent 10-K. While the company reported a Q4 net income, it was primarily due to a non-cash warrant adjustment, masking underlying operational losses. Investors should closely monitor the outcome of the FDA meeting regarding accelerated approval eligibility and the company's plans for securing additional financing.